Silvia Brugnatelli

ORCID: 0000-0003-0790-8380
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Treatment and Pharmacology
  • Colorectal Cancer Treatments and Studies
  • Multiple Myeloma Research and Treatments
  • Pancreatic and Hepatic Oncology Research
  • Nutrition and Health in Aging
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Gastric Cancer Management and Outcomes
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Neutropenia and Cancer Infections
  • Acute Myeloid Leukemia Research
  • Angiogenesis and VEGF in Cancer
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • COVID-19 and healthcare impacts
  • Cancer Cells and Metastasis
  • Immune Cell Function and Interaction
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Breast Cancer Treatment Studies
  • Peptidase Inhibition and Analysis
  • Nausea and vomiting management
  • Lung Cancer Research Studies
  • Glioma Diagnosis and Treatment
  • Clinical Nutrition and Gastroenterology
  • CAR-T cell therapy research
  • Protein Degradation and Inhibitors

Policlinico San Matteo Fondazione
2014-2024

Istituti di Ricovero e Cura a Carattere Scientifico
2015-2024

University of Pavia
2000-2023

Foundation Center
2021

Hudson Institute
2020

John Wiley & Sons (United States)
2020

Ospedale di Livorno
2009

University of Pisa
2009

University Hospital Foundation
2002

Associazione Italiana Di Oncologia Medica
1998-2001

Chiara Cremolini Carlotta Antoniotti Daniele Rossini Sara Lonardi Fotios Loupakis and 93 more Filippo Pietrantonio Roberto Bordonaro Tiziana Pia Latiano Emiliano Tamburini Daniele Santini Alessandro Passardi Federica Marmorino Roberta Grande Giuseppe Aprile Alberto Zaniboni Sabina Murgioni Cristina Granetto Angela Buonadonna Roberto Moretto Salvatore Corallo Stefano Cordio Lorenzo Antonuzzo Gianluca Tomasello Gianluca Masi Monica Ronzoni Samantha Di Donato Chiara Carlomagno Matteo Clavarezza Giuliana Ritorto Andrea Mambrini Mario Roselli Samanta Cupini Serafina Mammoliti Elisabetta Fenocchio E. Corgna Vittorina Zagonel Gabriella Fontanini Clara Ugolini Luca Boni Alfredo Falcone Alfredo Falcone Sara Lonardi Filippo de Braud Roberto Bordonaro Evaristo Maiello Emiliano Tamburini Daniele Santini Giovanni Luca Frassineti Teresa Gamucci Giuseppe Aprile Alberto Zaniboni Cristina Granetto Angela Buonadonna Francesco Di Costanzo Gianluca Tomasello Luca Gianni Samantha Di Donato Chiara Carlomagno Matteo Clavarezza Patrizia Racca Andrea Mambrini Mario Roselli Giacomo Allegrini Alberto Sobrero Massimo Aglietta E. Corgna Enrico Cortesi Domenico Corsi Alberto Ballestrero Andrea Bonetti Francesco Clemente Enzo Maria Ruggeri Fortunato Ciardiello Marco Benasso S. Vitello Saverio Cinieri Stefania Mosconi Nicola Silvestris Antonio Frassoldati S. Cupini Alessandro Bertolini Giampaolo Tortora Carmelo Bengala Daris Ferrari Antonia Ardizzoia Carlo Milandri Silvana Chiara Gianpiero Romano Stefania Miraglia Laura Scaltriti Francesca Pucci Livio Blasi Silvia Brugnatelli Luisa Fioretto Angela Stefania Ribecco Raffaella Longarini M. Frisinghelli Maria Banzi

10.1016/s1470-2045(19)30862-9 article EN The Lancet Oncology 2020-03-09

Abstract In recent years, whey proteins (WP) have attracted increasing attention in health and disease for their bioactive functions. The aim of this study was to evaluate the benefit WP isolate (WPI) supplementation addition nutritional counseling malnourished advanced cancer patients undergoing chemotherapy (CT). a single‐center, randomized, pragmatic, parallel‐group controlled trial ( ClinicalTrials.gov : NCT02065726), 166 with mixed tumor entities candidate or CT were randomly assigned...

10.1002/cam4.2517 article EN cc-by Cancer Medicine 2019-09-30

We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM). Between January 1987 and March 1993, 145 consecutive previously untreated patients with MM were between MPH-P (administered for 4 days every 6 weeks) only at disease progression. Survival was not influenced by either or progression (64 vs 71 months respectively). Comparing the first second group odds ratio death is...

10.1054/bjoc.1999.1087 article EN cc-by-nc-sa British Journal of Cancer 2000-04-01

Dendritic cells (DC) are central to the development of immune system responses. In a cohort 54 patients affected by colorectal cancer, we prospectively investigated number peripheral blood (PB) DC type 1 (DC1) and 2 (DC2) correlated their counts functionality stage disease vascular endothelial growth factor (VEGF) levels.At diagnosis, compared with healthy controls, presented reduced PBDC1 PBDC2 numbers (p < 0.001). Moreover, in cancer patients, PBDC showed low levels DC-associated antigens...

10.1159/000086784 article EN Oncology 2005-01-01

Environmental factors may play a role in colon cancer. In this view, several studies investigated tumor samples for the presence of various viral DNA with conflicting results.We undertook systematic analysis 44 consecutive, prospectively collected primary by real time and qualitative PCR viruses known or potential oncogenic humans, including polyomavirus (JCV, BKV, Merkel cell polyomavirus), HPV, HTLV, HHV-8 EBV. Negative controls consisted surgical resection margins. No evidence genomic...

10.1186/1750-9378-9-18 article EN cc-by Infectious Agents and Cancer 2014-06-03

Abstract Background Pancreatic adenocarcinoma is a high-mortality neoplasm with documented 5-years-overall survival around 5%. In the last decades, real breakthrough in treatment of disease has not been achieved. Here we propose prospective, phase II, multicentre, single-arm study aiming to assess efficacy and feasibility therapeutic protocol combining chemotherapy, carbon ion therapy surgery for resectable borderline pancreatic adenocarcinoma. Method The purpose this trial (PIOPPO Protocol)...

10.1186/s12885-019-6108-0 article EN cc-by BMC Cancer 2019-09-14

The overall risk of some cancers is increased in patients receiving regular dialysis treatment due to chronic oxidative stress, a weakened immune system and enhanced genomic damage. These could benefit from the same antineoplastic delivered with normal renal function, but better risk/benefit ratio be achieved by establishing specific guidelines. Key considerations are which chemotherapeutic agent use, adjustment dosages timing relation administration chemotherapy.We have reviewed available...

10.1136/esmoopen-2017-000167 article EN cc-by-nc ESMO Open 2017-01-01

Sacral chordoma (SC) is a neoplasm arising from residual notochordal cells degeneration. SC difficult to manage mainly because of anatomic location and tendency extensive spread. Carbon ion radiotherapy (CIRT) highly precise selectively deliver high biological effective dose the tumor target sparing anatomical structure on its path even if when contiguous intestine, surgical spacer might be an advantageous tool create distance around volume allowing radical curative delivery with safe...

10.1186/s12957-016-0966-6 article EN cc-by World Journal of Surgical Oncology 2016-08-09

Treatment of advanced metastatic colorectal cancer (mCRC) patients is associated with a poor prognosis and significant morbidity. Moreover, targeted therapies such as anti-epidermal growth factor receptor (EGFR) have no effect in tumors harboring mutation the RAS gene. The failure conventional treatment to improve outcomes mCRC has prompted development adoptive immunotherapy approaches including natural killer (NK)-based therapies. In this study, after confirmation that patients’ NK cells...

10.1097/cji.0000000000000205 article EN Journal of Immunotherapy 2017-12-29

Docetaxel associated with oxaliplatin and 5-fluorouracil (FLOT) has been reported as the best perioperative treatment for gastric cancer. However, there is still some debate about most appropriate number timing of chemotherapy cycles. In this randomized multicenter phase II study, patients resectable cancer were staged through laparoscopy peritoneal lavage cytology, randomly assigned (1:1) to either four cycles neoadjuvant (arm A) or two preoperative + postoperative docetaxel, oxaliplatin,...

10.3390/cancers12102790 article EN Cancers 2020-09-29

The COVID-19 outbreak has drastically changed practices inside hospitals, which include oncology routines. In oncology, malnutrition was and certainly still is a frequent problem associated with an increase in treatment-related toxicity, reduced response to cancer treatment, impaired quality of life, worse overall prognosis. Even this situation healthcare crisis, nutritional support care essential element. During the current pandemic, there concrete high risk see dramatic worsening patients'...

10.1007/s00520-020-05557-z article EN other-oa Supportive Care in Cancer 2020-06-03
Coming Soon ...